SG10201912768YA - Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder - Google Patents

Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Info

Publication number
SG10201912768YA
SG10201912768YA SG10201912768YA SG10201912768YA SG10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA SG 10201912768Y A SG10201912768Y A SG 10201912768YA
Authority
SG
Singapore
Prior art keywords
prophylaxis
treatment
blood coagulation
von willebrand
willebrand factor
Prior art date
Application number
SG10201912768YA
Inventor
Sabine Pestel
Elmar Raquet
Thomas Weimer
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of SG10201912768YA publication Critical patent/SG10201912768YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201912768YA 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder SG10201912768YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16198497 2016-11-11

Publications (1)

Publication Number Publication Date
SG10201912768YA true SG10201912768YA (en) 2020-02-27

Family

ID=57389201

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201912768YA SG10201912768YA (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
SG11201903954WA SG11201903954WA (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201903954WA SG11201903954WA (en) 2016-11-11 2017-11-10 Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder

Country Status (12)

Country Link
US (1) US11890327B2 (en)
EP (1) EP3538134B1 (en)
JP (1) JP2020504082A (en)
KR (1) KR20190073576A (en)
CN (1) CN110381986B (en)
AU (1) AU2017358865A1 (en)
CA (1) CA3043397A1 (en)
DK (1) DK3538134T3 (en)
ES (1) ES2908008T3 (en)
SG (2) SG10201912768YA (en)
TW (1) TW201828974A (en)
WO (1) WO2018087271A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019222682A1 (en) 2018-05-18 2019-11-21 Bioverativ Therapeutics Inc. Methods of treating hemophilia a
AU2020300820A1 (en) 2019-07-04 2022-03-03 CSL Behring Lengnau AG A truncated von willebrand factor (vWF) for increasing the in vitro stability of coagulation factor VIII
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii
KR102647642B1 (en) * 2021-05-04 2024-03-15 (주)케어젠 Peptides having blood coagulation activity and use thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
SE504074C2 (en) 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
IL113010A0 (en) 1994-03-31 1995-10-31 Pharmacia Ab Pharmaceutical formulation comprising factor VIII or factor ix with an activity of at least 200 IU/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
WO1996018412A1 (en) 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
WO1997003193A1 (en) 1995-07-11 1997-01-30 Chiron Corporation Novel factor viii:c polypeptide analogs with altered metal-binding properties
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
AT403764B (en) * 1996-03-15 1998-05-25 Immuno Ag STABLE FACTOR VIII / VWF COMPLEX
US20040092442A1 (en) 1996-04-24 2004-05-13 University Of Michigan Inactivation resistant factor VIII
EP0910628B1 (en) 1996-04-24 2006-03-08 The Regents of The University of Michigan Inactivation resistant factor viii
US6593294B1 (en) 1998-04-27 2003-07-15 Opperbas Holding B.V. Pharmaceutical composition comprising Factor VIII and neutral liposomes
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
JP2005518181A (en) 2001-01-12 2005-06-23 ジ・アメリカン・ナショナル・レッド・クロス Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII
WO2002103024A2 (en) 2001-06-14 2002-12-27 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
WO2003076567A2 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
DE60332011D1 (en) 2002-04-29 2010-05-20 Sanquin Bloedvoorziening ANTAGONISTS OF INTERACTION BETWEEN FACTOR VIII AND LRP (LOW-DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN)
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7199223B2 (en) 2003-02-26 2007-04-03 Nektar Therapeutics Al, Corporation Polymer-factor VIII moiety conjugates
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3552627A1 (en) 2003-05-06 2019-10-16 Bioverativ Therapeutics Inc. Clotting factor-fc chimeric proteins to treat hemophilia
SI1641823T1 (en) 2003-06-12 2011-12-30 Lilly Co Eli Glp-1 analog fusion proteins
RU2370276C2 (en) 2003-12-31 2009-10-20 Мерк Патент Гмбх Fc-ERYTHROPOIETIN FUSED PROTEIN WITH IMPROVED PHARMACOKINETICS
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
KR101483917B1 (en) 2004-11-12 2015-01-16 바이엘 헬스케어 엘엘씨 Site-directed modification of fviii
DK1835938T3 (en) 2004-12-27 2013-11-04 Baxter Int Polymer-von Willebrand factor conjugates
CA2604299A1 (en) 2005-04-14 2006-10-19 Csl Behring Gmbh Modified coagulation factor viii with enhanced stability and its derivates
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
MX2008012600A (en) 2006-03-31 2008-12-12 Baxter Int Pegylated factor viii.
EP2032607B2 (en) 2006-06-14 2017-02-22 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2008151817A1 (en) 2007-06-13 2008-12-18 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
DK2291523T3 (en) 2008-06-24 2015-03-23 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
RU2579977C2 (en) 2009-11-13 2016-04-10 Грифольс Терапьютикс Инк. PREPARATIONS CONTAINING VON WILLEBRAND FACTOR (vWF) AND METHODS, KITS AND APPLICATIONS RELATED TO THEM
WO2013093760A2 (en) 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
CN111499760A (en) 2012-01-12 2020-08-07 比奥贝拉蒂治疗公司 Chimeric factor VIII polypeptides and uses thereof
EP2814502B1 (en) 2012-02-15 2017-09-13 CSL Behring GmbH Von willebrand factor variants having improved factor viii binding affinity
US20150080309A1 (en) * 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
JP2015519313A (en) * 2012-04-24 2015-07-09 ノヴォ ノルディスク アー／エス Pharmaceutical composition suitable for the treatment of hemophilia
CN110054699A (en) 2012-07-11 2019-07-26 比奥贝拉蒂治疗公司 Factor IX compound with XTEN and vWF ELISA albumen, and application thereof
EP2796145B1 (en) * 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
WO2014198699A2 (en) 2013-06-12 2014-12-18 Novo Nordisk A/S Compounds suitable for treatment of haemophilia
ES2895798T3 (en) 2014-06-06 2022-02-22 Octapharma Ag Preparation comprising peptides of factor VIII and von Willebrand factor
CA2953593C (en) 2014-07-02 2023-09-26 Csl Limited Modified von willebrand factor
KR20180012303A (en) 2015-05-22 2018-02-05 체에스엘 베링 리컴비넌트 퍼실리티 아게 Method for producing modified von Willebrand factor

Also Published As

Publication number Publication date
WO2018087271A1 (en) 2018-05-17
US11890327B2 (en) 2024-02-06
EP3538134A1 (en) 2019-09-18
KR20190073576A (en) 2019-06-26
CA3043397A1 (en) 2018-05-17
US20210268071A1 (en) 2021-09-02
EP3538134B1 (en) 2021-12-29
ES2908008T3 (en) 2022-04-27
CN110381986A (en) 2019-10-25
SG11201903954WA (en) 2019-05-30
DK3538134T3 (en) 2022-02-07
TW201828974A (en) 2018-08-16
AU2017358865A1 (en) 2019-05-09
JP2020504082A (en) 2020-02-06
CN110381986B (en) 2023-08-18

Similar Documents

Publication Publication Date Title
PL3554631T3 (en) Treating patients with ttfields with the electrode positions optimized using deformable templates
SG10201912768YA (en) Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder
HK1254280A1 (en) Molecular constructs for preventing the formation of blood clot and/or treating thrombosis
BR112017011722A2 (en) activin-actrii antagonists and uses for treating anemia
DK3197472T3 (en) RECOMBINANT PHE-FREE PROTEINS FOR USE IN THE TREATMENT OF PHENYLKETONURI
PL3405222T3 (en) Novel polypeptides and medical uses thereof
HK1248714A1 (en) Mutated fragments of the ras protein
IL257173A (en) Novel insulin derivatives and the medical uses hereof
HK1250625A1 (en) Truncated von willebrand factor polypeptides for treating hemophilia
IL269853A (en) Proteins for the treatment of epithelial barrier function disorders
IL262752B (en) Construction of engineering bacteria for high expression of recombinant human serum albumin
EP3229859B8 (en) Dialysis machine for monitoring the time changes of the hematocrit and/or hemoglobin value
EP3256158A4 (en) Tolerance therapeutic for treating polypeptide induced allergy
IL249294A0 (en) Preparation comprising factor viii and von willebrand factor peptides
EP3328440A4 (en) Treatment using truncated trk b and trk c antagonists
GB201612165D0 (en) Combinations for the treatment of type 2 diabetes
DE112017006267A5 (en) CONTROL DEVICE FOR AN IMPLANTABLE HEART PUMP WITH TWO IMPLANTABLE CONTROL UNITS AND WITH A CONNECTABLE SWITCH CONNECTED TO THEM
SG10201912360SA (en) Truncated von willebrand factor polypeptides for treating hemophilia
MA50358A (en) SEMAGLUTIDE IN MEDICAL THERAPY
DK3641795T3 (en) METHODS AND MATERIALS FOR TREATING BLOOD VESSELS
MX2016003871A (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins.
SG11201703624PA (en) Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers
AR104194A1 (en) VON WILLEBRAND FACTOR COMPOSITION
PL3233110T3 (en) Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
SG11201706819RA (en) Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease